|
|
|
|
Increased Survival TimeCanine Melanoma Vaccine, DNA makes use of a non-canine gene to stimulate immunity in the dog (see How the New Vaccine Works). This type of vaccine technology has been proven in five-year trials involving more than 100 dogs with canine oral melanoma that had already received surgery and/or radiation to remove local tumors.1
NOTICE: The USDA has issued a conditional U.S. Veterinary Biological Product License for this therapeutic vaccine. This conditional license is a response to an application and assurance of safety and purity, and a reasonable expectation of efficacy based on initial trials.1,2 During this period of conditional license, additional research will be conducted to further support the safety and efficacy of the vaccine. Production under this license is in compliance with all regulations and standards applicable to such products.1Bergman PJ, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24:4582-4585. |
More Info 1 No. But when used as directed, this vaccine causes the immune system to recognize and attack melanoma tumor cells. 2 Canine Melanoma Vaccine is administered using a needle-free transdermal device. The device is especially matched to this vaccine to deliver the vaccine in a way that allows optimal distribution of vaccine. |
 |
